Sugi Predict

Sugi Predict / Compounds / SCHEMBL9938726

SCHEMBL9938726

SCHEMBL9938726

Cc1cc2c(N)ccc(Cl)c2nc1Nc1cc(C(F)(F)F)ccn1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 7/20 0.40
▸ NOS3 P29474 1/20 0.39
▸ NOS2 P35228 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAP3K12 Q12852 2/20 0.36
▸ IDH2 P48735 1/20 0.36
▸ TEAD1 P28347 1/20 0.36
▸ EPAS1 Q99814 1/20 0.35
▸ SLC40A1 Q9NP59 1/20 0.34
▸ AURKA O14965 1/20 0.34
▸ RPS6KB1 P23443 1/20 0.34
▸ CTSC P53634 1/20 0.34
▸ MDM2 Q00987 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9965286 0.90 SYK (0.42) SYKNOS3NOS2ALDH1A1L3MBTL1
SCHEMBL25894573 0.84 SYK (0.38) SYKALDH1A1L3MBTL1LMNAGLA
SCHEMBL20124507 0.83 SYK (0.37) SYKALDH1A1L3MBTL1LMNAGLA
SCHEMBL9965317 0.82 NOS3 (0.42) SYKNOS3NOS2ALDH1A1L3MBTL1
SCHEMBL9943626 0.80 ALDH1A1 (0.42) SYKALDH1A1L3MBTL1LMNAGLA
SCHEMBL9972399 0.80 IDH2 (0.41) SYKNOS3NOS2ALDH1A1L3MBTL1
SCHEMBL9938767 0.77 NR4A2 (0.36) NOS3NOS2LMNA
SCHEMBL9943213 0.76 KDM4E (0.42) SYKALDH1A1
SCHEMBL20124470 0.76 PIM1 (0.38) SYKNOS3NOS2ALDH1A1L3MBTL1
SCHEMBL9939018 0.71 CSF1R (0.39) SYKGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651416-B1 COMPOUNDS USEFUL FOR TREATING AIDS ABIVAX (FR) 2018-05-09 — — EP claimed
US-9061999-B2 Compounds useful for treating AIDS ABIVAX (FR) 2015-06-23 — — US claimed
US-20130267703-A1 COMPOUNDS USEFUL FOR TREATING AIDS SPLICOS (FR) 2013-10-10 — — US claimed
EP-2465502-A1 Compounds useful for treating AIDS Société Splicos (FR) 2012-06-20 — — EP claimed
EP-4215196-A1 COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR ABIVAX (FR) 2023-07-26 — — EP disclosed
WO-2023135207-A1 COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR ABIVAX (FR) 2023-07-20 — — WO disclosed
EP-4212156-A1 COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR ABIVAX (FR) 2023-07-19 — — EP disclosed
US-20220145406-A1 BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER ABIVAX (FR) 2022-05-12 — — US disclosed
US-20220023324-A1 QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES ABIVAX (FR) 2022-01-27 — — US disclosed
EP-3261642-B1 QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL INFECTION ABIVAX (FR) 2021-05-19 — — EP disclosed
EP-3261642-B1 QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL INFECTION ABIVAX (FR) 2021-05-19 — — EP disclosed
US-10806729-B2 Quinoline derivatives for use in the treatment or prevention of viral infection ABIVAX (FR) 2020-10-20 — — US disclosed
US-9061999-B2 Compounds useful for treating AIDS ABIVAX (FR) 2015-06-23 — — US disclosed
EP-2651416-A1 COMPOUNDS USEFUL FOR TREATING AIDS Splicos (FR) 2013-10-23 — — EP disclosed
US-20130267703-A1 COMPOUNDS USEFUL FOR TREATING AIDS SPLICOS (FR) 2013-10-10 — — US disclosed
US-20130267703-A1 COMPOUNDS USEFUL FOR TREATING AIDS SPLICOS (FR) 2013-10-10 — — US disclosed
US-20130267703-A1 COMPOUNDS USEFUL FOR TREATING AIDS SPLICOS (FR) 2013-10-10 — — US disclosed
WO-2012080953-A1 COMPOUNDS USEFUL FOR TREATING AIDS SPLICOS (FR) 2012-06-21 — — WO disclosed
EP-2465502-A1 Compounds useful for treating AIDS Société Splicos (FR) 2012-06-20 — — EP disclosed
EP-2465502-A1 Compounds useful for treating AIDS Société Splicos (FR) 2012-06-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267703-A1 COMPOUNDS USEFUL FOR TREATING AIDS CBR3, CBR1, CCR10 SYK 1956/4885NOS3 30/4885NOS2 130/4885
US-20220023324-A1 QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES NR1H3, NR1H2, NR1H4 SYK 1176/4885NOS3 25/4885NOS2 105/4885
US-10806729-B2 Quinoline derivatives for use in the treatment or prevention of viral infection CD4, SLC11A2, NQO2 SYK 3031/4885NOS3 393/4885NOS2 217/4885
US-20220145406-A1 BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER HAVCR2, CXCL8, IL36G SYK 2246/4885NOS3 2445/4885NOS2 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.